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Wilms’ tumor-1: a riddle wrapped 
in a mystery, inside a kidney
Jordan A. Kreidberg1,2 and Sunny Hartwig1,2
After more than 15 years of intense study, WT1 remains a complex 
protein with multiple functions and targets. This Commentary 
discusses new developments and puts past results in perspective.
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In 1990, Wilms’ tumor-1 (WT1),1,2 named 
for the eponymous tumor, was identi-
fied as one of a newly emerging class of 
tumor suppressor genes. In 1993, it was 
demonstrated that the gene knockout 
of Wt1 in mice results in bilateral renal 
agenesis.3 This finding not only dem-
onstrated an essential role for Wt1 in 
murine renal development but was one 
of the first knockout mouse models to 
show a developmental organ agenesis 
phenotype. Pioneering work in the field 
of WT1 research suggested that this gene, 
which exhibited properties of a tumor 
suppressor, was expressed and required 
in the developing urogenital system 
and a few other organs. Yet less than 20 
years later, a search in PubMed reveals 
over 3,000 publications on WT1 and its 
encoded zinc-finger protein—and an 
ever-growing body of evidence suggests 
that WT1, now known to be broadly 
expressed in both developing and adult 
tissues, plays an important role in many 
developing and mature organs, as well 
as in tumors. Indeed, a cursory glance 
at the most recent citations in PubMed 
might just as easily suggest a function 
for WT1 in the immune, hematopoi-
etic, or nervous system as in the kidney, 
and perhaps imply a more important 
relevance of WT1 to tumor biology 
than to development or glomerular kid-
ney disease.
How can we account for this huge 
amassment of literature concerning 
WT1? Certainly, the discovery that WT1 
encodes a protein with both a zinc finger 
and a nuclear localization domain, and 
was therefore probably acting as a tran-
scriptional regulator, has been a key event 
in the history of WT1-related research, 
the upshot of which has been the ongo-
ing effort to identify the ‘smoking gun’ 
transcriptional gene target or targets that 
account for the renal and gonadal agen-
esis observed in Wt1-homozygous-null 
mouse embryos. These efforts were aided 
by the realization that the Krüppel-type 
(Cys2His2) zinc-finger domain of WT1 
resembled that of the transcription fac-
tor EGR1,4 the latter being known to 
bind specific GC-rich DNA sequences 
upstream of the transcriptional start site 
of many genes.
Based on these initial observations, 
a plethora of in vitro co-transfection 
studies were published (reviewed by 
Scharnhorst et al.5) that followed a 
common basic pattern: a candidate pro-
moter target of WT1 was screened for 
GC-rich sequences or other puta-
tive WT1-responsive DNA sequences 
upstream of its transcriptional start site. 
Where identified, these sequences were 
cloned into a reporter construct and 
co-transfected with a WT1-expressing 
plasmid into immortalized cells. In 
addition to the GC-rich sequence, other 
binding sequences were also found for 
WT1 (see, for example, Wang et al.6). 
Co-transfection studies were usually 
accompanied by other experiments, 
including DNA footprinting, electro-
phoretic mobility shift assays, and some-
times demonstrations that expression 
of the endogenous gene (as opposed to 
that of a reporter construct) could also be 
affected by overexpression of WT1.
Results of co-transfection experiments 
were confounding, as they demonstrated 
that WT1 acted as either a transcriptional 
activator or repressor, depending on the 
gene target, and contradictory results 
were sometimes obtained depending 
on the cell line, expression vector, or 
culture conditions used. In addition, 
these experiments suffered from other 
limitations associated with the in vitro 
environment, including the generation 
of WT1 expression levels far above physi-
ological levels, the questionable validity 
of using immortalized cell lines as mod-
els for various tissues, and the possibil-
ity that footprinting and electrophoretic 
mobility shift assays might not accurately 
reflect DNA assembly into chromatin in 
vivo (although some recent studies have 
used chromatin immunoprecipitation 
experiments7). Notably, targeted muta-
tion of the promising gene targets thus 
identified in vitro failed to recapitulate or 
approximate the murine Wt1-null phe-
notype in vivo. In fairness, however, it is 
increasingly apparent that Wt1 does not 
behave as a classical transcription factor; 
it is thus unlikely that the developmen-
tal Wt1-null phenotypes are due to the 
misexpression of a single Wt1 target gene, 
nor perhaps of even a few target genes. 
Furthermore, as WT1 is now known to 
be expressed in a broad range of adult tis-
sues and tumors (see, for example, Hosen 
et al.8), targets that might a few years ago 
have seemed irrelevant in the urogeni-
tal system might actually be important 
targets in other cell types, both normal 
and neoplastic.
In addition to its function as a tran-
scription factor, a growing body of evi-
dence suggests that WT1 may play an 
equally if not more important role in 
post-transcriptional regulation. Certainly, 
the existence of four major alternatively 
spliced isoforms, as well as 62 additional 
possible isoforms due to alternative trans-
lational start sites,9 is suggestive of multi-
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ple functions of WT1. Moreover, anyone 
who has done a western blot for WT1 can 
attest to the presence of multiple bands 
whose detection and relative expression 
levels vary depending on the tissue source 
and antibody used. These results raise the 
question of whether all such bands are 
attributable to WT1, or whether they 
might belong to as-yet unidentified WT1-
related proteins whose function has hith-
erto been erroneously ascribed to WT1.
Among its known isoforms, WT1 
appears to have at least one major 
function distinct from its role in tran-
scriptional regulation, namely mRNA 
processing. One of the two alternative 
splicing events results in the inclusion 
or omission of three amino acids, KTS, 
at the end of the third zinc finger. Inclu-
sion of KTS appears to disrupt the DNA-
binding properties of WT1 and produces 
a characteristic speckled nuclear pattern 
of WT1 expression, suggesting an asso-
ciation with the nuclear matrix or with 
splicing apparatus. Further molecular 
studies have demonstrated interactions 
of WT1 with the splicing apparatus10 and 
shown that expression of the +KTS form 
can affect the stability or alternative splic-
ing of certain mRNAs, including vascular 
endothelial growth factor-A (VEGF-A).
VEGFA is a particularly interesting 
potential target for WT1. Denys–Drash 
syndrome, a rare congenital disease 
caused by mutations in WT1, is associ-
ated with altered expression of VEGF-A 
isoforms.11 Overexpression of WT1 in 
the mesenchyme of metanephric organ 
cultures results in an increase in VEGF-A 
mRNA levels.12 Mechanistically, in vitro 
evidence in nonrenal cells suggests 
that WT1 may affect VEGFA mRNA 
transcription and stability.13 Notably, 
these observations suggest that during 
organogenesis, WT1 may help regulate 
micro-interactions between the devel-
oping epithelial structures and adjacent 
developing vasculature, as in the forma-
tion of glomerular capillaries. However, it 
has yet to be demonstrated at a molecular 
level that WT1 directly regulates VEGFA 
expression in podocytes.
Steege et al.14 (this issue) identify a 
new WT1 target in renin, a well-known 
component of the renin–angiotensin 
system that regulates blood pressure. 
Specifically, renin is an aspartyl-protease 
that cleaves the pre-propeptide angio-
tensinogen to produce the propeptide 
angiotensin I, the immediate precursor 
to the active hypertensive peptide angio-
tensin II. Steege et al.14 demonstrate, 
using several molecular assays, includ-
ing chromatin immunoprecipitation, 
that WT1 may regulate transcription of 
the renin gene. They demonstrate that 
WT1 is expressed in afferent arterioles, a 
previously unknown site of WT1 expres-
sion. Importantly, these data suggest that 
WT1 may not only regulate vasculogen-
esis in a paracrine fashion from adjacent 
epithelial cell types but might play a 
direct role within the developing vascu-
lature itself. Additionally, although not 
examined by Steege et al.,14 renin expres-
sion has been detected in podocytes,15 
and thus, WT1 may also have a role 
regulating renin expression within the 
glomerulus. Collectively, these obser-
vations support the hypothesis that 
WT1 regulates expression of multiple 
target genes, including those encoding 
VEGF-A and renin. These observations 
also raise the question of whether WT1 
regulates not only morphogenesis, but 
also ongoing physiological processes 
throughout life — a query especially 
pertinent to the study of the glomeru-
lus. As the dynamic nature of podocytes 
and their foot processes becomes better 
understood, we may find that a critical 
relationship exists between morphology 
and physiology; and to the extent that 
foot processes might remodel to respond 
to subclinical or even pathogenic events 
throughout life, it is possible that pro-
teins whose expression is regulated by 
WT1 play an important role in these 
responses. Recent observations are 
beginning to point us in that direction.
In conclusion, WT1 is a far more 
complicated protein (or family of closely 
related proteins) than initially suspected. 
Far from acting as a conventional tran-
scription factor with a single or a few 
gene targets, WT1 may play multiple, 
even numerous and disparate roles both 
during development and in adult organ 
maintenance. From the viewpoint of the 
twenty-first-century molecular biolo-
gist, this makes the study of WT1 both 
an exciting challenge and an enigma. 
Why in embryogenesis is there apopto-
sis in the absence of a tumor suppressor 
gene?3 This seems contradictory on the 
face of it. Just as we think we might be 
coming to terms with its diverse func-
tions, a new Pandora’s box opens and 
a new set of problems presents itself. It 
seems that it will be a while before this 
protein gives up its many mysteries.
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